1
|
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro Oncol 2023; 25:146-156. [PMID: 35639513 PMCID: PMC9825299 DOI: 10.1093/neuonc/noac139] [Citation(s) in RCA: 17] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation. METHODS This was an open-label, multicenter, nonrandomized, phase Ib/II clinical trial. Eligible patients (≥18 years) had histologically confirmed IDH1R132X-mutated glioma that relapsed or progressed on or following standard therapy and had measurable disease. Patients received olutasidenib, 150 mg orally twice daily (BID) in continuous 28-day cycles. The primary endpoints were dose-limiting toxicities (DLTs) (cycle 1) and safety in phase I and objective response rate using the Modified Response Assessment in Neuro-Oncology criteria in phase II. RESULTS Twenty-six patients were enrolled and followed for a median 15.1 months (7.3‒19.4). No DLTs were observed in the single-agent glioma cohort and the pharmacokinetic relationship supported olutasidenib 150 mg BID as the recommended phase II dose. In the response-evaluable population, disease control rate (objective response plus stable disease) was 48%. Two (8%) patients demonstrated a best response of partial response and eight (32%) had stable disease for at least 4 months. Grade 3‒4 adverse events (≥10%) included alanine aminotransferase increased and aspartate aminotransferase increased (three [12%], each). CONCLUSIONS Olutasidenib 150 mg BID was well tolerated in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation and demonstrated preliminary evidence of clinical activity in this heavily pretreated population.
Collapse
Affiliation(s)
- Macarena I de la Fuente
- Sylvester Comprehensive Cancer Center and Department of Neurology, University of Miami, Miami, Florida, USA
| | - Howard Colman
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
| | - Mark Rosenthal
- Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
| | - Brian A Van Tine
- Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
| | - Danijela Levacic
- Baylor and Scott White Vasicek Cancer Center, Baylor University Temple, Temple, Texas, USA
| | - Tobias Walbert
- Henry Ford Cancer Institute, Henry Ford Health System and Wayne State University, Detroit, Michigan, USA
| | - Hui K Gan
- Olivia Newton-John Cancer Wellness and Research Centre Austin Hospital, Heidelberg, Victoria, Australia
| | - Maria Vieito
- Vall d’Hebron Institute of Oncology, Barcelona, Spain
| | - Mohammed M Milhem
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA
| | | | | | | | | | | | - Julie Brevard
- Forma Therapeutics, Inc., Watertown, Massachusetts, USA
| | | | | | - Varun Monga
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA
| |
Collapse
|
2
|
Methot JL, Zhou H, McGowan MA, Anthony NJ, Christopher M, Garcia Y, Achab A, Lipford K, Trotter BW, Altman MD, Fradera X, Lesburg CA, Li C, Alves S, Chappell CP, Jain R, Mangado R, Pinheiro E, Williams SMG, Goldenblatt P, Hill A, Shaffer L, Chen D, Tong V, McLeod RL, Lee HH, Yu H, Shah S, Katz JD. Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators. J Med Chem 2021; 64:5137-5156. [PMID: 33797901 DOI: 10.1021/acs.jmedchem.1c00237] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The approvals of idelalisib and duvelisib have validated PI3Kδ inhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors with excellent isoform and kinome selectivity; however, they had high projected human doses. Improved ligand contacts gave potency enhancements, while replacement of metabolic liabilities led to extended half-lives in preclinical species, affording PI3Kδ inhibitors with low once-daily predicted human doses. Treatment of C57BL/6-Foxp3-GDL reporter mice with 30 and 100 mg/kg/day of 3c (MSD-496486311) led to a 70% reduction in Foxp3-expressing regulatory T cells as observed through bioluminescence imaging with luciferin, consistent with the role of PI3K/AKT signaling in Treg cell proliferation. As a model for allergic rhinitis and asthma, treatment of ovalbumin-challenged Brown Norway rats with 0.3 to 30 mg/kg/day of 3c gave a dose-dependent reduction in pulmonary bronchoalveolar lavage inflammation eosinophil cell count.
Collapse
Affiliation(s)
- Joey L Methot
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Hua Zhou
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Meredeth A McGowan
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Neville John Anthony
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Matthew Christopher
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Yudith Garcia
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Abdelghani Achab
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Kathryn Lipford
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Benjamin Wesley Trotter
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Michael D Altman
- Computational and Structural Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Xavier Fradera
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Charles A Lesburg
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Chaomin Li
- Process Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Stephen Alves
- Discovery Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Craig P Chappell
- Discovery Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Renu Jain
- Discovery Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Ruban Mangado
- Discovery Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Elaine Pinheiro
- Discovery Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Sybill M G Williams
- Discovery Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Peter Goldenblatt
- In Vitro Pharmacology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Armetta Hill
- In Vitro Pharmacology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Lynsey Shaffer
- In Vitro Pharmacology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Dapeng Chen
- Preclinical Pharmacokinetics and Drug Metabolism, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Vincent Tong
- Preclinical Pharmacokinetics and Drug Metabolism, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Robbie L McLeod
- In Vivo Pharmacology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Hyun-Hee Lee
- In Vivo Pharmacology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Hongshi Yu
- Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Sanjiv Shah
- In Vitro Pharmacology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| | - Jason D Katz
- Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States
| |
Collapse
|